125 related articles for article (PubMed ID: 37015847)
21. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer.
Pos FJ; Horenblas S; Lebesque J; Moonen L; Schneider C; Sminia P; Bartelink H
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):696-705. PubMed ID: 15183473
[TBL] [Abstract][Full Text] [Related]
22. Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): a patterns of care study.
Erickson B; Eifel P; Moughan J; Rownd J; Iarocci T; Owen J
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1083-92. PubMed ID: 16099599
[TBL] [Abstract][Full Text] [Related]
23. High-dose-rate brachytherapy of primary cutaneous B-cell lymphoma: the first reported case series.
Chyrek AJ; Bielȩda GM; Burchardt WM; Chicheł A
J Contemp Brachytherapy; 2020 Jun; 12(3):241-247. PubMed ID: 32695195
[TBL] [Abstract][Full Text] [Related]
24. High-dose-rate brachytherapy boost for locally advanced cervical cancer: Oncological outcome and toxicity analysis of 4 fractionation schemes.
le Guyader M; Lam Cham Kee D; Thamphya B; Schiappa R; Gautier M; Chand-Fouche ME; Hannoun-Levi JM
Clin Transl Radiat Oncol; 2022 Jan; 32():15-23. PubMed ID: 34816022
[TBL] [Abstract][Full Text] [Related]
25. Perioperative hyperfractionated high-dose rate brachytherapy for the treatment of soft tissue sarcomas: multicentric experience.
Petera J; Soumarová R; Růzicková J; Neumanová R; Dusek L; Sirák I; Macingová Z; Paluska P; Kasaová L; Hodek M; Vosmik M
Ann Surg Oncol; 2010 Jan; 17(1):206-10. PubMed ID: 19711130
[TBL] [Abstract][Full Text] [Related]
26. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
27. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
[TBL] [Abstract][Full Text] [Related]
28. HDR and LDR Brachytherapy in the Treatment of Lip Cancer: the Experience of the Catalan Institute of Oncology.
Ayerra AQ; Mena EP; Fabregas JP; Miguelez CG; Guedea F
J Contemp Brachytherapy; 2010 Mar; 2(1):9-13. PubMed ID: 28031737
[TBL] [Abstract][Full Text] [Related]
29. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control.
Mayrata E; Espinosa JM; Büchser D; Casquero F; Suárez F; González A; Minguez P; Pérez JF; Miguel IS; Cacicedo J; Gómez-Iturriaga A
J Contemp Brachytherapy; 2021 Feb; 13(1):12-17. PubMed ID: 34025731
[TBL] [Abstract][Full Text] [Related]
30. High dose rate brachytherapy in early stage squamous-cell carcinoma of the lip.
Mut A; Guinot JL; Arribas L; Díez-Presa L; Tortajada MI; Santos MÁ; Samper J; Santamaría P; Vendrell JB
Acta Otorrinolaringol Esp; 2016; 67(5):282-7. PubMed ID: 27063585
[TBL] [Abstract][Full Text] [Related]
31. Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer.
Armstrong S; Tsang Y; Lowe G; Tharmalingam H; Alonzi R; Ostler P; Hughes R; Hoskin P
Radiother Oncol; 2021 Apr; 157():93-98. PubMed ID: 33493500
[TBL] [Abstract][Full Text] [Related]
32. Treatment results of high-dose-rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimens.
Wong FC; Tung SY; Leung TW; Sze WK; Wong VY; Lui CM; Yuen KK; O SK
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1254-64. PubMed ID: 12654435
[TBL] [Abstract][Full Text] [Related]
33. Late effects of post-high-dose-rate brachytherapy for oropharyngeal carcinoma: are they severer than post-low-dose-rate?
Nose T; Peiffert D; Lapeyre M; Hoffstetter S; Koizumi M; Nishiyama K
Strahlenther Onkol; 2004 Dec; 180(12):776-82. PubMed ID: 15592697
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
Makino T; Mizokami A; Namiki M
Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
[TBL] [Abstract][Full Text] [Related]
35. Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity.
Henríquez I; Sancho G; Hervás A; Guix B; Pera J; Gutierrez C; Abuchaibe O; Martínez-Monge R; Tormo A; Polo A
Radiat Oncol; 2014 Apr; 9():102. PubMed ID: 24885287
[TBL] [Abstract][Full Text] [Related]
36. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
Pellizzon AC; Salvajoli J; Novaes P; Maia M; Fogaroli R; Gides D; Horriot R
Int J Med Sci; 2008 Jun; 5(3):113-20. PubMed ID: 18566673
[TBL] [Abstract][Full Text] [Related]
37. Definitive high-dose-rate endobronchial brachytherapy of bronchial stump for lung cancer after surgery.
Skowronek J; Piorunek T; Kanikowski M; Chicheł A; Bielęda G
Brachytherapy; 2013; 12(6):560-6. PubMed ID: 23850277
[TBL] [Abstract][Full Text] [Related]
38. High versus low dose rate intracavitary irradiation for adenocarcinoma of the uterine cervix.
Kim WC; Kim GE; Suh CO; Loh JJ
Jpn J Clin Oncol; 2001 Sep; 31(9):432-7. PubMed ID: 11689597
[TBL] [Abstract][Full Text] [Related]
39. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer.
Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423
[TBL] [Abstract][Full Text] [Related]
40. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
